Pfizer’s Sickle Cell Disease Candidate Fails Phase III Trial

Pfizer’s Sickle Cell Antibody Drug Fails in Phase III

Inclacumab, Pfizer’s candidate sickle cell antibody therapeutic, has failed to reach its primary endpoint in a Phase III trial called THRIVE-131. “We recognize this news is disappointing for the sickle cell community, and we share their disappointment,” said Michael Vincent, MD, PhD, chief inflammation & immunology officer, Pfizer, in a press statement about the trial results. “While the THRIVE-131 results did not meet our expectations, we remai…

Pharma Pulse: GLP-1 Access Partnership, Pfizer’s Sickle Cell Setback, and Patient Portal Trade-Offs

This episode of Pharma Pulse covers a new collaboration to expand access to GLP-1 therapies via LillyDirect, Pfizer’s Phase III miss in sickle cell disease, and how patient portals are improving access to care while creating new workload challenges for providers.

Pfizer’s sickle cell disease candidate fails Phase III trial

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.The post Pfizer’s sickle cell disease candidate fails Phase III trial appeared first on Clinical Trials Arena.